Clinical trials: Metastatic Colorectal Neoplasms
Colorectal Cancer
Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
- Trial name
- NCT00467129
- Testing
- microarray analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 800 people
- Sponsor
- University of Sheffield
Colorectal Neoplasm
SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer
The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (SOX) and Oxaliplatin and Capecitabine (XELOX) in patients with peritoneal metastasis of colorectal cancer.
- Trial name
- NCT02870153
- Testing
- SOX, XELOX
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First People's Hospital of Changzhou
Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has…
- Conditions
- Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- PRIMIER (NCT02413853)
- Testing
- CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium
- Where
- United States
- Sponsor
- University of Southern California
Colorectal Cancer
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00873275
- Testing
- bevacizumab, FOLFOX regimen, fluorouracil
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer
Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva
Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).
- Trial name
- ACT (NCT00598156)
- Testing
- erlotinib (Tarceva), bevacizumab (Avastin)
- Where
- 15 sites in Denmark, Sweden
- Volunteers
- 249 people
- Sponsor
- Lund University Hospital
Metastatic Colorectal Cancer
Nitazoxanide in Patients With Metastatic Colorectal Cancer
The aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in patients with metastatic colorectal cancer.
- Trial name
- NCT06049901
- Testing
- Nitazoxanide
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Metastatic Colorectal Cancer
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy
- Trial name
- NCT06551207
- Testing
- Fruquintinib, Cadonilimab, SBRT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Liu Huang
Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at…
- Trial name
- VELO (NCT05468892)
- Testing
- Trifluridine Tipiracil, Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
- Where
- 8 sites in Italy
- Volunteers
- 68 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Carcinoma
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.
- Trial name
- NCT02935764
- Testing
- Irinotecan, 5-fluorouracil, Leucovorin
- Volunteers
- 164 people
- Sponsor
- Fudan University
Colorectal Cancer
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
- Trial name
- CC6 (NCT02118064)
- Testing
- G17DT-Irinotecan
- Volunteers
- 161 people
- Sponsor
- Cancer Advances Inc.
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to…
- Trial name
- NCT01858662
- Testing
- Metastases Resection ( multiple steep surgery possible), 5-Fluorouracile, leucovorin L
- Where
- 7 sites in Belgium
- Volunteers
- 4 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Colorectal Cancer
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat…
- Trial name
- ICE (NCT01387880)
- Testing
- Everolimus
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Herlev Hospital
Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Colorectal Carcinoma (mCRC)
OSCAR II STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm, dual cohort Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in either mPDAC or mCRC…
- Trial name
- NCT06655142
- Testing
- ONCObind (Onco-Seraph) 100 Filter, Matched Controls
- Volunteers
- 120 people
- Sponsor
- ExThera Medical Corporation
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Cancer, Colon Cancer
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy in patients with…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- BAH248 (NCT06530303)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Colorectal Carcinoma Metastatic in the Liver
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals…
- Trial name
- METEORITE (NCT06555133)
- Testing
- yttrium-90 radioembolization
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Colorectal Cancer Metastatic
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
Patient with multiple metastases, not eligible for surgery, might not profit from intensive chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease control may be a better choice for first line…
- Trial name
- NCT01249638
- Testing
- Capecitabine, Bevacizumab, Irinotecan
- Where
- Germany
- Volunteers
- 516 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.